ロード中...

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Zhao, Hongbo, Huang, Yutang, Shi, Jingjing, Dai, Yi, Wu, Lanxiang, Zhou, Honghao
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6256088/
https://ncbi.nlm.nih.gov/pubmed/30515095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01312
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!